Literature DB >> 7729326

Daily life cardiac ischaemia. Should it be treated?

B D Bertolet1, C J Pepine.   

Abstract

Daily life cardiac ischaemia is defined as reversible myocardial cellular hypoxia that occurs during activities of daily living, without artificial provocation. Most of these daily life ischaemic episodes are not associated with symptoms. However, it is not practical to distinguish silent versus symptomatic daily life ischaemia as both are associated with haemodynamic abnormalities and future adverse outcomes. Daily life cardiac ischaemia is best detected using ambulatory electrocardiogram (ECG) monitoring; however, there are other diagnostic tools (e.g. exercise treadmill) that can be used. Once detected, the optimal therapy for daily life myocardial ischaemia has yet to be identified. However, it does appear that usual antianginal medications including nitrates, beta-blockers, calcium antagonists and antiplatelet drugs are effective in reducing the incidence and severity of daily life myocardial ischaemia. Medical therapy and revascularisation should be utilised to obliterate all episodes of daily life cardiac ischaemia to prevent future cardiac events. Moreover, the efficacy of the chosen therapeutic regimen for each patient should be documented with follow-up objective testing. The diagnosis and management of daily life myocardial ischaemia is continually evolving. Future research as well as economic considerations will shape future management strategies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729326     DOI: 10.2165/00003495-199549020-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  94 in total

1.  Effects of long-acting propranolol on A.M. and P.M. peaks in silent myocardial ischemia.

Authors:  P F Cohn; W E Lawson
Journal:  Am J Cardiol       Date:  1989-04-01       Impact factor: 2.778

2.  Effects of atenolol alone, nifedipine alone and their combination on ambulant myocardial ischemia.

Authors:  J A Hill; J I Gonzalez; R Kolb; C J Pepine
Journal:  Am J Cardiol       Date:  1991-04-01       Impact factor: 2.778

3.  Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group.

Authors:  P H Stone; R S Gibson; S P Glasser; M A DeWood; J D Parker; D T Kawanishi; M H Crawford; F C Messineo; T L Shook; K Raby
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

4.  Usefulness of Holter monitoring for detecting myocardial ischemia in patients with nondiagnostic exercise treadmill test.

Authors:  K E Raby; J Barry; C B Treasure; G Hirsowitz; G Fantasia; A P Selwyn
Journal:  Am J Cardiol       Date:  1993-10-15       Impact factor: 2.778

5.  Intravenous nitroglycerin infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed canine coronary arteries.

Authors:  J D Folts; J Stamler; J Loscalzo
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

6.  Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST)

Authors:  C J Pepine; P F Cohn; P C Deedwania; R S Gibson; E Handberg; J A Hill; E Miller; R G Marks; U Thadani
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

7.  Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris.

Authors:  S M Johnson; D R Mauritson; J R Corbett; W Woodward; J T Willerson; L D Hillis
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

8.  Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. The Tissue Plasminogen Activator: Toronto (TPAT) Study Group.

Authors:  A Langer; J Minkowitz; P Dorian; L Casella; L Harris; C D Morgan; P W Armstrong
Journal:  J Am Coll Cardiol       Date:  1992-11-15       Impact factor: 24.094

9.  Transdermal nitroglycerin patches for silent myocardial ischemia during antianginal treatment.

Authors:  A Schneeweiss; A Marmor
Journal:  Am J Cardiol       Date:  1988-03-25       Impact factor: 2.778

10.  Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina.

Authors:  G G Neri Serneri; G F Gensini; L Poggesi; F Trotta; P A Modesti; M Boddi; A Ieri; M Margheri; G C Casolo; M Bini
Journal:  Lancet       Date:  1990-03-17       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.